Company Encyclopedia
View More
name
MICROTECH MED-B
02235.HK
MicroTech Medical (Hangzhou) Co., Ltd. provides diabetes management, diabetes treatment, and diabetes monitoring medical devices in China and internationally. The company offers Equil patch insulin pump systems; AiDEX and LinX continuous glucose monitoring systems; POCT analyzer systems; closed-loop artificial pancreas systems; blood glucose monitoring systems; Exactive Pro blood glucose, blood ketone, and uric acid monitoring system; API open platform; and diabetes digital management software. It also involved in scientific research and technical services; business services; wholesale and retail; manufacturing; and commercials business.
132.85 B
02235.HKMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking18/26
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-1.39%D
    • Profit Margin-6.28%D
    • Gross Margin51.66%B
  • Growth ScoreA
    • Revenue YoY50.53%A
    • Net Profit YoY80.76%A
    • Total Assets YoY3.73%C
    • Net Assets YoY-0.32%C
  • Cash ScoreC
    • Cash Flow Margin-1592.48%E
    • OCF YoY50.53%A
  • Operating ScoreD
    • Turnover0.2D
  • Debt ScoreA
    • Gearing Ratio10.80%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CITIC Construction Investment: Maintain "Buy" rating on MICROTECH MED-B, with CGM volume driving high performance growth

    CITIC Construction Investment maintains a "Buy" rating for MICROTECH MED-B, expecting operating revenue to reach 531 million, 789 million, and 1.066 billion yuan in 2025, 2026, and 2027 respectively, with significant growth in net profit attributable to the parent company. The company benefits from the rapid expansion of CGM products and is expected to continue high-speed growth in the second half of the year, especially in domestic and international markets. The core product Equil patch insulin pump has been approved for expanded indications, which is expected to drive performance growth. In the medium to long term, the company's leading position in diabetes management will be further consolidated

    Zhitong·
    HK
    02235
    -1.04%
    Zhitong·
    HK
    02235
    -1.04%

    MICROTECH MED-B cancels 60,000 repurchased shares

    According to the Zhitong Finance APP, MICROTECH MED-B announced that the company will cancel 60,000 repurchased shares on September 26, 2025

    Zhitong·
    HK
    02235
    -1.04%
    Zhitong·
    HK
    02235
    -1.04%

    MICROTECH MED-B: Adhesive Insulin Pump for Children and Adolescents Indications Approved

    MICROTECH MED-B announced that its Equil patch insulin pump for children and adolescents has been approved by the National Medical Products Administration, expanding its applicability to diabetic patients aged 3-17. This approval provides millions of children and adolescents with new treatment options, with clinical trials led by the Children's Hospital affiliated with Zhejiang University School of Medicine, demonstrating the effectiveness and safety of CSII in this population. The product has several advantages over traditional insulin pumps, further consolidating the company's industry-leading position

    Zhitong·
    HK
    02235
    -1.04%
    Zhitong·
    HK
    02235
    -1.04%

    CD Capital GP Ltd reduced its holdings in MICROTECH MED-B by 93,200 shares at an average price of HKD 8.61 per share

    According to the latest information from the Hong Kong Stock Exchange, on September 12, CD Capital GP Ltd reduced its holdings in MICROTECH MED-B by 93,200 shares, with an average price of HKD 8.61 per share, totaling approximately HKD 802,500. After the reduction, the latest number of shares held is approximately 8.3968 million, with a latest holding ratio of 4.96%. This transaction involves other related parties: CD Capital Healthcare FUND V, L.P., CDBI GP, Ltd, CDBI Partners Fund I, L.P., CDBI Partners Fund II, L.P., CDBI Partners GP, Ltd, Master Summer Limited

    Zhitong·
    HK
    02235
    -1.04%
    Zhitong·
    HK
    02235
    -1.04%

    "Performance" MICROTECH MED's mid-term loss narrowed to 2.29 million RMB

    MICROTECH MED-B announced its interim results for the six months ending in June, with operating revenue of RMB 246 million, an increase of 63.1% year-on-year; gross profit of RMB 127 million, up 57.7%. The loss narrowed significantly from RMB 37.74 million in the same period last year to RMB 2.29 million, mainly benefiting from the expansion of sales scale and the deepening of comprehensive budget control to enhance operational efficiency; loss per share is 0.5 cents. No dividend is declared

    AASTOCKS·
    HK
    02235
    -1.04%
    AASTOCKS·
    HK
    02235
    -1.04%
    © 2025 Longbridge｜Disclaimer